SA
Go ProLog In
LRMR
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
75
Score
8 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
8100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
+235.2%
Consensus
$12.00
+235.2%
Bull
$12.00
+235.2%
12-Month Target Range8 analysts
$12.00$12.00$12.00
Current $3.58Consensus
Current Price
$3.58
Upside to Consensus
$8.42

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+2499.13%
EPS—
FY2028
Rev+151.03%
EPS—
FY2029
Rev+77.24%
EPS—

Earnings Surprises

Recent Analyst Actions

Mar 3, 2026Wedbush
Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush
Target:$12.00
+119.2%from $5.47
Sep 30, 2025Robert W. Baird
Larimar Therapeutics price target lowered to $7 from $10 at Baird
Target:$7.00
+107.1%from $3.38
Dec 17, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)
Target:$15.00
+250.5%from $4.28
Oct 30, 2024Citigroup
Citi Reiterates Buy Rating on Larimar Therapeutics (LRMR), Opens 90-Day Upside Catalyst Watch
Target:$14.00
+65.5%from $8.46
Oct 3, 2024Wedbush
Wedbush bullish on Larimar Therapeutics, initiates with an Outperform
Target:$22.00
+249.8%from $6.29
Apr 3, 2024Leerink Partners
Leerink bullish on Larimar Therapeutics, initiates with an Outperform
Target:$25.00
+230.3%from $7.57
Dec 13, 2022Citigroup
Citigroup Initiates Coverage On Larimar Therapeutics with Neutral Rating, Announces Price Target of $4
Target:$4.00
+0.8%from $3.97

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance